Antibiotic · Glycopeptide
Vancomycin (Vancocin)
Also called Vancocin, vanc
Indications
- Serious infections from methicillin-resistant staphylococci: septicemia, endocarditis, bone, lower respiratory tract and skin infections (label)
- Serious staphylococcal infection in penicillin-allergic patients or when other drugs fail (label)
- Empiric MRSA coverage in sepsis, pneumonia, meningitis and line infection, with a beta-lactam, stopped when cultures exclude it
- C. difficile colitis and staphylococcal enterocolitis, by mouth (label)
Dosing
| Where | Dose |
|---|---|
| Antimicrobials | Vancomycin: Load by weight; maintenance by AUC or levels |
On the quick cards
Mechanism of action
Vancomycin is a glycopeptide whose bactericidal action comes mainly from blocking cell-wall synthesis; it also alters membrane permeability and RNA synthesis (label). It binds the D-alanyl-D-alanine end of peptidoglycan precursors, which stops their transfer and cross-linking. It is inactive against gram-negative bacilli (label), because the large molecule cannot cross their outer membrane. Enterococci with vanA or vanB genes build D-Ala-D-lactate ends instead, the basis of VRE.
Pharmacology
- Infectious: staphylococci including MRSA, streptococci and enterococci (enterococcal endocarditis only with an aminoglycoside); inactive against gram-negative bacilli, mycobacteria and fungi (label)
- Skin and cardiovascular: rapid infusion can cause flushing, itching and exaggerated hypotension, including shock and rarely cardiac arrest (label); histamine-mediated, formerly red man syndrome
- Renal: AKI rises with exposure, and trough-guided dosing caused more nephrotoxicity than AUC dosing (IDSA/ASHP 2020)
- Ear and blood: ototoxicity, mostly with excessive doses, prior hearing loss or other ototoxic drugs; reversible neutropenia, usually after a week or more (label)
Pharmacokinetics
| Half-life | 4–6 h with normal kidneys; about 7.5 days if anephric (label) |
|---|---|
| Distribution | 0.3–0.43 L/kg (label) |
| Protein binding | About 55% (label) |
| Metabolism | None apparent (label) |
| Elimination | About 75% in urine within 24 h by glomerular filtration (label) |
| Target | AUC 400–600 mg·h/L assuming an MIC of 1, best by Bayesian software; trough-only 15–20 mg/L no longer recommended (IDSA/ASHP 2020) |
| Loading | 20–35 mg/kg actual weight in critical illness, at most 3,000 mg (IDSA/ASHP 2020) |
| Dialysis | Poorly removed by standard dialysis (label); keep pre-dialysis levels 15–20 mg/L (IDSA/ASHP 2020) |
| CRRT | Load 20–25 mg/kg, then 7.5–10 mg/kg every 12 h at 20–25 mL/kg/h effluent (IDSA/ASHP 2020) |
Chemistry
- Tricyclic glycopeptide from Amycolatopsis orientalis; C₆₆H₇₅Cl₂N₉O₂₄·HCl, MW 1485.74 (label)
- Large and polar: no metabolism, renal elimination and no gram-negative penetration
- Reconstituted pH 2.5–4.5 (label); acidic, so dilute to no more than 5 mg/mL and infuse over at least 60 min, no faster than 10 mg/min (label)
- Physically incompatible with beta-lactam solutions (label)
Adverse effects and cautions
In the one-pagers
Practice Neuro: ICP and Stroke questions free55 exam-style questions with rationales on the topic where Vancomycin comes up most. No account or download needed.
In the algorithms
Other antibiotic drugs
Practice free in your browser2,450+ exam-style questions with rationales. No account, no ads. Also free on the App Store and Google Play.
Sources
- FDA label: Vancomycin HCl for Injection (Xellia, 2022)
- FDA label: Vancomycin HCl for Injection (Hospira, 2021)
- Rybak 2020 (IDSA/ASHP/PIDS/SIDP vancomycin guideline)
For education and exam preparation only. Follow your institution’s protocols. Typical adult values for study. Follow your local protocols and medical direction.